Open AccessPatient-Reported Outcomes Support First-Line Pembrolizumab in TNBC
Author(s) -
Peter M. Goodwin
Publication year - 2022
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000839968.78822.60
Subject(s) - pembrolizumab , medicine , oncology , quality of life (healthcare) , chemotherapy , cancer , breast cancer , immunotherapy , triple negative breast cancer , nursing